Biotechnology Ultrasector Profund Fund Manager Performance Evaluation
| BIPIX Fund | USD 65.12 1.96 3.10% |
The fund shows a Beta (market volatility) of 1.74, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biotechnology Ultrasector will likely underperform.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biotechnology Ultrasector Profund has generated negative risk-adjusted returns adding no value to fund investors. In spite of latest weak performance, the Fund's forward indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the fund investors.
...more| Expense Ratio Date | 30th of November 2022 | |
| Expense Ratio | 1.5400 |
Biotechnology |
Biotechnology Ultrasector Relative Risk vs. Return Landscape
If you would invest 7,172 in Biotechnology Ultrasector Profund on August 24, 2024 and sell it today you would lose (856.00) from holding Biotechnology Ultrasector Profund or give up 11.94% of portfolio value over 90 days. Biotechnology Ultrasector Profund is currently producing negative expected returns and takes up 2.0279% volatility of returns over 90 trading days. Put another way, 18% of traded mutual funds are less volatile than Biotechnology, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Biotechnology Ultrasector Current Valuation
Overvalued
Today
Please note that Biotechnology Ultrasector's price fluctuation is very steady at this time. At this time, the entity appears to be overvalued. Biotechnology Ultrasector shows a prevailing Real Value of $58.95 per share. The current price of the fund is $65.12. We determine the value of Biotechnology Ultrasector from analyzing fund fundamentals and technical indicators as well as its Probability Of Bankruptcy. In general, we favor acquiring undervalued mutual funds and dropping overvalued mutual funds since, at some point, mutual fund prices and their ongoing real values will blend.
Since Biotechnology Ultrasector is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biotechnology Mutual Fund. However, Biotechnology Ultrasector's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 65.12 | Real 58.95 | Hype 63.16 | Naive 57.09 |
The intrinsic value of Biotechnology Ultrasector's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biotechnology Ultrasector's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biotechnology Ultrasector Profund helps investors to forecast how Biotechnology mutual fund's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biotechnology Ultrasector more accurately as focusing exclusively on Biotechnology Ultrasector's fundamentals will not take into account other important factors: Biotechnology Ultrasector Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotechnology Ultrasector's investment risk. Standard deviation is the most common way to measure market volatility of mutual funds, such as Biotechnology Ultrasector Profund, and traders can use it to determine the average amount a Biotechnology Ultrasector's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0877
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIPIX |
Estimated Market Risk
| 2.03 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biotechnology Ultrasector is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biotechnology Ultrasector by adding Biotechnology Ultrasector to a well-diversified portfolio.
Biotechnology Ultrasector Fundamentals Growth
Biotechnology Mutual Fund prices reflect investors' perceptions of the future prospects and financial health of Biotechnology Ultrasector, and Biotechnology Ultrasector fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biotechnology Mutual Fund performance.
| Price To Earning | 2.37 X | |||
| Price To Book | 5.19 X | |||
| Price To Sales | 4.56 X | |||
| Total Asset | 113.86 M | |||
About Biotechnology Ultrasector Performance
Evaluating Biotechnology Ultrasector's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Biotechnology Ultrasector has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biotechnology Ultrasector has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
The fund invests in financial instruments that the fund advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index represents the biotechnology segment of the SP Total Market Index, which comprises the following sub-industry biotechnology. The fund is non-diversified.Things to note about Biotechnology Ultrasector performance evaluation
Checking the ongoing alerts about Biotechnology Ultrasector for important developments is a great way to find new opportunities for your next move. Mutual Fund alerts and notifications screener for Biotechnology Ultrasector help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biotechnology Ultrasector generated a negative expected return over the last 90 days | |
| The fund generated three year return of 0.0% | |
| Biotechnology Ultrasector holds about 24.54% of its assets under management (AUM) in cash |
- Analyzing Biotechnology Ultrasector's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biotechnology Ultrasector's stock is overvalued or undervalued compared to its peers.
- Examining Biotechnology Ultrasector's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biotechnology Ultrasector's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biotechnology Ultrasector's management team can help you assess the Mutual Fund's leadership.
- Pay attention to analyst opinions and ratings of Biotechnology Ultrasector's mutual fund. These opinions can provide insight into Biotechnology Ultrasector's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Biotechnology Mutual Fund
Biotechnology Ultrasector financial ratios help investors to determine whether Biotechnology Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Ultrasector security.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |